Loading...
XNAS
ORKA
Market cap4.79bUSD
Oct 08, Last price  
77.28USD
1D
-2.79%
1Q
-10.96%
Jan 2017
-87.45%
IPO
-100.00%
Name

ARCA Biopharma Inc

Chart & performance

D1W1MN
XNAS:ORKA chart
P/E
—
P/S
—
EPS
—
Div yield, %
2.03%
Shrs. gr., 5y
57.47%
Rev. gr., 5y
%
Revenues
0
3,888,00046,861,000000000000000000000
Net income
-105m
L+25.93%
-132,776,999-12,301,000-19,431,000-9,138,000-8,420,000-5,364,000-4,320,000-6,939,000-9,689,000-11,445,000-16,443,999-18,490,000-7,933,000-5,482,000-9,738,000-19,322,000-9,926,000-5,339,000-83,724,000-105,433,000
CFO
-88m
L+52.51%
-37,060,000-45,958,000-18,401,000-41,726,000-8,324,000-6,959,000-4,078,000-5,288,000-9,406,000-10,534,000-14,987,000-17,472,000-8,244,000-4,801,000-7,725,000-18,762,000-10,912,000-5,014,000-57,837,000-88,210,000
Dividend
Aug 29, 20241.613 USD/sh

Notes

No notes on this company yet
Write a private note on this company, for your eyes only
Add note

Profile

ARCA biopharma, Inc. operates as a clinical-stage biopharmaceutical company dedicated to the creation and commercialization of genetically targeted therapies designed to address various cardiovascular ailments. The company's leading therapeutic programs feature two key candidates: Recombinant Nematode Anticoagulant Protein c2 (rNAPc2), known as AB201, which is currently being evaluated in a Phase IIb clinical trial for its potential in treating COVID-19. Gencaro (bucindolol hydrochloride), a distinctive pharmacogenetically-targeted beta-adrenergic receptor antagonist. This compound has already concluded its Phase IIb trial, demonstrating efficacy for the management of atrial fibrillation in patients afflicted with chronic heart failure. To further its research and development efforts, ARCA biopharma has established strategic collaborations. These include a partnership with LabCorp aimed at developing a genetic test for the GENETIC-AF clinical trial, as well as a research alliance with the Colorado Prevention Center (an academic research organization of the University of Colorado) focused on advancing and commercializing Gencaro. Founded in 2004, the company is based in Westminster, Colorado.

Key people

Michael R. Bristow
President, Chief Executive Officer, Director · since 2009
Thomas A. Keuer
Chief Operating Officer · since 2014
Brian L. Selby
Chief Accounting Officer, Principal Accounting Officer, Vice President - Finance · since 2014
Christopher David Ozeroff
Senior Vice President, General Counsel, Secretary · since 2009
Linda Grais
Lead Independent Director
Anders D. Hove
Director · since 2017
Daniel Mitchell
Director · since 2014
Raymond L. Woosley
Director · since 2013
URL
https://arcabio.com/
IPO date
Jul 21, 2000
Employees
5
Domiciled in
US
Incorporated in
US
Legal address
c/o THE CORPORATION TRUST COMPANY, CORPORATION TRUST CENTER 1209 ORANGE ST
WILMINGTON, DE 19801
US
Headquarters
11080 CirclePoint Rd., Suite 140
Westminster, CO 80020
US
Previous name
ARCA BIOPHARMA, INC.

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2025‑122024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT